ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 10 for:    teva migraine

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02629861
Recruitment Status : Completed
First Posted : December 14, 2015
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

Brief Summary:
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine

Condition or disease Intervention/treatment Phase
Migraine Drug: TEV-48125 - 1 Drug: TEV-48125 - 2 Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 875 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine
Actual Study Start Date : February 22, 2016
Actual Primary Completion Date : April 10, 2017
Actual Study Completion Date : April 10, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Migraine

Arm Intervention/treatment
Experimental: TEV-48125 - 1
Dose Regimen 1
Drug: TEV-48125 - 1
Subcutaneous administration Dose Regimen 1
Other Name: monoclonal antibody

Experimental: TEV-48125 - 2
Dose Regimen 2
Drug: TEV-48125 - 2
Subcutaneous administration Dose Regimen 2
Other Name: monoclonal antibody

Placebo Comparator: Placebo
Matching Placebo
Drug: Placebo
Matching Placebo




Primary Outcome Measures :
  1. Mean change from baseline in the monthly average number of migraine days [ Time Frame: Baseline, 12 weeks ]

Secondary Outcome Measures :
  1. Proportion of patients reaching at least 50% reduction in the monthly average number of migraine days [ Time Frame: Baseline, 12 weeks ]
  2. Mean change from baseline in the monthly average number of days of use of any acute headache medications [ Time Frame: Baseline, 12 weeks ]
  3. Mean change from baseline in the number of migraine days [ Time Frame: Baseline, 4-week ]
  4. Mean change from baseline in disability, as measured by the Migraine Disability Assessment (MIDAS) questionnaire [ Time Frame: Baseline, 12 weeks ]
    The MIDAS questionnaire assesses headache-related disability based on number of days and severity.

  5. Mean change from baseline in the monthly average number of migraine days in patients not receiving concomitant migraine preventive medications [ Time Frame: Baseline, 12 weeks ]

Other Outcome Measures:
  1. Occurrence of adverse events throughout the study [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females aged 18 to 70 years, inclusive, with migraine onset at ≤50 years of age
  • Patient signs and dates the informed consent document
  • Patient has history of migraine according to International Classification of Headache Disorders, or clinical judgment suggests a migraine diagnosis
  • 85% e-diary compliance
  • Total body weight between 99 and 265 lbs, inclusive

    • Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

  • Clinically significant hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease, at the discretion of the investigator
  • Evidence or medical history of clinically significant psychiatric issues, including any suicide attempt in the past, or suicidal ideation with a specific plan in the past 2 years
  • History of clinically significant cardiovascular disease or vascular ischemia (such as myocardial, neurological [eg, cerebral ischemia], peripheral extremity ischemia, or other ischemic event) or thromboembolic events (arterial or venous thrombotic or embolic events), such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism
  • Known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection
  • Past or current history of cancer in the last 5 years, except for appropriately treated nonmelanoma skin carcinoma
  • Pregnant or nursing females
  • History of hypersensitivity reactions to injected proteins, including monoclonal antibodies
  • Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months or 5 half-lives, whichever is longer

    • Additional criteria apply, please contact the investigator for more information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02629861


  Show 139 Study Locations
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Investigators
Study Director: Teva Medical Expert, MD Teva Pharmaceuticals USA

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc.
ClinicalTrials.gov Identifier: NCT02629861     History of Changes
Other Study ID Numbers: TV48125-CNS-30050
2015-004598-34 ( EudraCT Number )
First Posted: December 14, 2015    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: April 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs